Prostate cancer is now one of the most commonly diagnosed cancers in the UK, with over 400,000 men living with #prostate cancer in the UK.

Today, via a new in-license partnership that enables us to distribute a new treatment option for men living with hormone-sensitive advanced prostate cancer, we continue to build on our leadership position in #oncology whilst underpinning our commitment to supporting access to medicines for people with #cancer.

We want to say thank you to our talented team that played such a large part in this milestone. Because today, our team really did make it better at Accord.